SOPHiA GENETICS SA (SOPH)
| Market Cap | 630.80M +108.4% |
| Revenue (ttm) | 86.17M +23.6% |
| Net Income | -80.88M |
| EPS | -1.16 |
| Shares Out | 85.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 328,117 |
| Open | 7.32 |
| Previous Close | 7.30 |
| Day's Range | 7.07 - 7.46 |
| 52-Week Range | 3.75 - 8.98 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 9.75 (+31.58%) |
| Est. Earnings | Nov 3, 2026 |
About SOPH
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North Americ... [Read more]
Financial Performance
In 2025, SOPHiA GENETICS's revenue was $77.27 million, an increase of 18.56% compared to the previous year's $65.17 million. Losses were -$79.00 million, 26.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SOPH stock is "Strong Buy." The 12-month stock price target is $9.75, which is an increase of 31.58% from the latest price.
News
Myriad, Sophia advance prostate cancer-specific genomic instability score tech
Myriad Genetics (MYGN) and Sophia Genetics (SOPH) announced a collaboration to advance new prostate cancer-specific genomic instability score technology to support precision oncology approaches with A...
Sophia Genetics and Myriad Genetics collaborate in prostate cancer score tech
Sophia Genetics (SOPH) and Myriad Genetics (MYGN) announced a collaboration to advance new prostate cancer-specific genomic instability score technology – or PrGIS – to support precision oncology appr...
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) t...
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability...
Sophia Genetics price target raised to $9 from $8 at BTIG
BTIG analyst Mark Massaro raised the firm’s price target on Sophia Genetics (SOPH) to $9 from $8 and keeps a Buy rating on the shares. Sophia Genetics delivered a strong…
Sophia Genetics price target raised to $14 from $12 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Sophia Genetics (SOPH) to $14 from $12 and keeps a Buy rating on the shares post the Q2 report.
Sophia Genetics reports Q2 EPS (30c), one estimate (22c)
Reports Q2 revenue $23.3M, consensus $21.72M. Performance was driven by 60% volume growth in the U.S. and 80% revenue growth in Liquid Biopsy. We delivered an outstanding second quarter, growing…
Sophia Genetics raises FY26 revenue view to $94M-$96M from $92M-$94M
Consensus $93.38M. The company also expects an adjusted EBITDA loss between $29M and $32M.
SOPHiA GENETICS Earnings Call Transcript: Q2 2026
Q2 2026 saw 27% revenue growth and strong U.S. performance, with new CDx deals and a JV with MSK fueling future growth. Guidance was raised to $94M-$96M, and adjusted EBITDA loss improved 27% year-over-year. Cash reserves now stand at $107.7M.
SOPHiA GENETICS Earnings release: Q2 2026
SOPHiA GENETICS released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
SOPHiA GENETICS Slides: Q2 2026
SOPHiA GENETICS has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
SOPHiA GENETICS Reports Second Quarter 2026 Results
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter end...
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) s...
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for ...
Sophia Genetics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Sophia Genetics (SOPH) with a Buy rating and $12 price target Sophia integrates AI with multimodal genomic and clinical data to support oncology and rare-disease…
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July...
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced un...
Sophia Genetics 10.5M share Spot Secondary priced at $4.75
TD Cowen acted as sole book running manager for the offering.
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares
BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced un...
Sophia Genetics $40M Spot Secondary re-offered at $4.75
17:41 EDT Sophia Genetics (SOPH) $40M Spot Secondary re-offered at $4.75
Sophia Genetics announces ordinary share offering, no amount given
Sophia Genetics (SOPH) announced the commencement of a proposed underwritten public offering of its ordinary shares. TD Cowen is acting as the lead book-running manager for the offering. Published fir...
SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares
BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritte...
Sophia Genetics appoints Ross Muken as CEO
Sophia Genetics (SOPH) confirmed, ahead of its 2026 Annual General Meeting scheduled for June 18, the leadership changes first announced in January 2026. The Board has appointed Ross Muken, currently…
SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting
Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board BOSTON and ROLLE, Switzerland, June 10, 2...
Sophia Genetics management to meet with BTIG
Life Science and Diagnostic Tools Analyst Massaro holds a meeting with management in New York on June 10 hosted by BTIG.